Core Insights - The article discusses the upcoming IPO of Yuwang Biological, a leading fish oil supplier in China, which holds an 8.1% share of the global market and aims to become the first fish oil stock from Shandong [5][29]. Company Overview - Yuwang Biological has evolved from a soybean protein manufacturer to a global leader in food-grade refined fish oil over 30 years, capitalizing on the health consumption upgrade trend [5][6]. - The company was founded by Liu Xiqian, who transitioned from soybean protein to fish oil in the 1990s, establishing the "Forget Me Not" brand and becoming the first domestic producer of DHA/EPA standard products [7][9][10]. - The company has expanded its global presence, exporting to over 60 countries and becoming a key supplier for dietary supplement brands [11][12]. Financial Performance - Yuwang Biological's net profit has more than doubled from 2022 to 2024, reflecting its growth in global market share [14]. - The company plans to use funds from its IPO to strengthen its supply chain, sales channels, and R&D efforts, addressing financial pressures with a debt ratio exceeding 90% by 2024 [29][32]. Market Challenges - The company faces significant risks due to its reliance on external suppliers for raw materials, with 90% of its costs tied to purchasing crude fish oil, primarily imported from Peru [18][19]. - Yuwang's sales strategy heavily depends on third-party traders, which compromises its pricing power and customer relationships [21][22]. - The fish oil market has experienced negative growth from 2020 to 2023, and while there is a slight recovery expected, the growth rate remains low [28]. Competitive Landscape - Competitors like Xinmeijia and international brands such as Swisse have invested significantly in R&D and maintain higher profit margins through direct sales channels [25][26]. - The global fish oil market is shifting from volume expansion to value competition, with a projected growth rate of only 7.9% over the next five years [28]. Future Strategies - Yuwang aims to establish an overseas procurement base in Peru and sign long-term contracts for crude fish oil to mitigate raw material price volatility [29]. - The company plans to develop a direct sales team in Europe and North America to reduce reliance on traders and enhance revenue from direct sales [30]. - R&D investments will focus on pharmaceutical-grade fish oil and specialized products for infants and pets to diversify its product offerings [31].

Core Viewpoint - Yuwang Bio plans to go public on the Hong Kong Stock Exchange, but its recent performance has raised concerns about its growth trajectory and market position [1][2]. Financial Performance - Yuwang Bio showed strong growth from 2022 to 2024, with revenues of 534 million, 661 million, and 832 million yuan, reflecting year-on-year growth rates of 23.71% and 25.92% [1]. - Net profits also increased during this period, reaching 67 million, 102 million, and 125 million yuan, with growth rates of 51.41% and 22.96% [1]. - However, in the first half of 2025, revenues dropped to 343 million yuan, a significant decline of 27.13% compared to 471 million yuan in the first half of 2024 [1]. - Net profit plummeted from 87.59 million yuan in the first half of 2024 to 22.76 million yuan in the first half of 2025, a decrease of 74.01% [1]. Product Line and Revenue Sources - Refined fish oil and fish oil soft capsules have been the core product lines for Yuwang Bio, contributing approximately 97.5% to 98.8% of total revenue from 2022 to the first half of 2025 [2]. - The revenue from refined fish oil decreased by 42.5% from 156 million yuan in the first half of 2024 to 90 million yuan in the first half of 2025, primarily due to falling average selling prices [2]. Market Position - Yuwang Bio is the largest supplier of food-grade refined fish oil globally, holding an 8.1% market share based on sales volume in 2024 [3]. - The company's sales are primarily divided into three categories: dietary supplement brand manufacturers, trading companies and pharmaceutical wholesalers, and direct consumer sales [3]. - In the first half of 2025, sales to dietary supplement brand manufacturers accounted for 45.2% of total revenue, while trading companies and wholesalers contributed 52.1% [3]. Brand Performance - Despite endorsements from the National Youth Development Promotion Association, the "Wang Bule" brand has struggled to resonate with the "Z Generation," with low sales figures compared to competitors [4]. - The "Wang Bule" brand's flagship product has significantly lower sales on platforms like Tmall and JD compared to leading brands such as Swisse, which has achieved sales of over 100,000 units for similar products [4]. - The brand's limited market presence and weaker promotional efforts have resulted in lower recognition among younger consumers compared to established international brands [4].